Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 19 (3), 245-51

The Effect of Adropin on Lipid and Glucose Metabolism in Rats With Hyperlipidemia

Affiliations

The Effect of Adropin on Lipid and Glucose Metabolism in Rats With Hyperlipidemia

Raziye Akcılar et al. Iran J Basic Med Sci.

Abstract

Objectives: The aim of this study was to evaluate, for the first time, whether the effects of low-dose adropin administration is effective in rats with hyperlipidemia.

Materials and methods: Twenty one Wistar albino female rats were randomly divided into 3 groups and fed with high-fat diet for 4 weeks to establish the hyperlipidemia model. Meanwhile, adropin was administrated intraperitonealy (2.1 μg/kg/day), once a day for continuous 10 days. Then, body weights and serum biochemical parameters, adropin, insulin and blood glucose levels were determined. Additionally, in liver tissue, inducible nitric oxide synthase (iNOS), tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) mRNA gene expressions were evaluated by RT-PCR.

Results: The results showed that intraperitoneal administration of adropin to hyperlipidemic rats for 10 days were extremely effective in decreasing the levels of serum triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT), and gamma glutamil transferase (GGT) and increasing the levels of high density lipoprotein cholesterol (HDL-C). It could decrease mRNA expressions of pro-inflammatory cytokines TNF-α and IL-6 via regulating the expressions of iNOS. In addition, treatment with adropin showed a significant reduction in blood glucose, serum insulin levels, HbA1c (%), and HOMA-IR, and increase in serum adropin levels.

Conclusion: Adropin may ameliorate lipid metabolism, reduce insulin resistance, and inhibit hepatocytes inflammation. Thus, adropin had significant therapeutic benefits and could be suggested as a potential candidate agent against hyperlipidemia.

Keywords: Adropin; Blood glucose; High-fat diet; Insulin; Lipid metabolism.

Figures

Figure 1
Figure 1
Serum adropin concentrations in control, hyperlipidemic, and adropin-treated groups of rats; * Shows significance between H and A groups (P≤0.05) (Mann Whitney U test); C: control, H: hyperlipidemic, and A: adropin-treated groups
Figure 2
Figure 2
TNF-α/β-actin ratio in control, hyperlipidemic, and adropin-treated groups of rat; * Shows significance between groups C and H (P≤0.05) (Mann Whitney U test), † Shows significance between groups H and A (P≤0.05) (Mann Whitney U test); C: control, H: hyperlipidemic, A: adropin treatment groups, TNF-α: Transforming growth factor-alpha.
Figure 3
Figure 3
IL-6/β-actin ratio in control, hyperlipidemic, and adropin-treated groups of rats; * Shows significance between groups H and A (P≤0.05) (Mann Whitney U test); C: control, H: hyperlipidemic, A: adropin treatment groups, IL-6: Interleukin 6
Figure 4
Figure 4
iNOS/β-actin ratio in control, hyperlipidemic, and adropin-treated groups of rats; * Shows significance between groups C and H (P≤0.05) (Mann Whitney U test); † Shows significance between groups H and A (P≤0.05) (Mann Whitney U test); C: control, H: hyperlipidemic, A: adropin treatment groups, iNOS: inducible nitric oxide synthase

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

See all "Cited by" articles

References

    1. Suk HY, Zhou C, Yang TT, Zhu H, Yu RY, Olabisi O, Yang X, Brancho D, Kim JY, Scherer PE, Frank PG, Lisanti MP, Calvert JW, Lefer DJ, Molkentin JD, Ghigo A, Hirsch E, Jin J, Chow CW. Ablation of calcineurin Aβreveals hyperlipidemia and signaling cross-talks with phosphodiesterases. J Biol Chem. 2013;288:3477–3488. - PMC - PubMed
    1. Pöss J, Custodis F, Werner C, Weingärtner O, Böhm M, Laufs U. Cardiovascular disease and dyslipidemia: beyond LDL. Curr Pharm Des. 2011;17:861–870. - PubMed
    1. Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31:189–196. - PubMed
    1. Lu ZL, Xu ZM, Kou WR, Zhao SP. Advance in basic and clinical research of Xuezhikang capsule. Chin J Integr Med. 2006;12:85–93. - PubMed
    1. Priego T, Sa´nchez J, Pico´ C, Palou A. Sex-differential expression of metabolism- related genes in response to a high-fat diet. Obesity. 2008;16:819–826. - PubMed
Feedback